Aptevo Therapeutics (APVO) Total Current Liabilities (2015 - 2026)

Aptevo Therapeutics has reported Total Current Liabilities for 12 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Total Current Liabilities fell 11.74% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 11.74% YoY) and the FY2025 annual result came in at $6.0 million, down 2.53% from the prior year.
• Total Current Liabilities eased to $4.8 million in Q1 2026 per APVO's latest filing, from $6.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $23.9 million in Q1 2022 and troughed at $4.8 million in Q1 2026.
• A 5-year average of $7.3 million and a median of $6.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities slumped 77.31% in 2022, then rose 8.64% in 2024.
• Over 5 years, Total Current Liabilities stood at $8.7 million in 2022, then retreated by 17.02% to $7.2 million in 2023, then slipped by 14.08% to $6.2 million in 2024, then declined by 2.53% to $6.0 million in 2025, then dropped by 21.32% to $4.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $4.8 million, $6.0 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.